Connecticut Patent of the Month – June 2024

Thetis Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, is at the forefront with a groundbreaking approach using resolvins, specifically resolvin E1 (“RvE1”). This natural compound, part of the specialized pro-resolving mediators (SPMs), plays a crucial role in resolving inflammation, which is increasingly recognized as a pivotal factor in cancer progression and treatment.

Traditional methods have often relied on daily administration to maintain therapeutic levels of RvE1 due to its rapid metabolism and short half-life in the body. However, Thetis Pharmaceuticals has innovated with a novel approach—a less than daily (LTD) dosing regimen. This regimen, administered every six or seven days, harnesses the therapeutic potential of RvE1 while circumventing the need for continuous administration. This not only enhances patient convenience but also addresses the challenge of maintaining consistent therapeutic levels over time.

The method involves administering a pharmaceutical composition containing a mineral amino acid salt of RvE1, ensuring stability and bioavailability. This composition can be used alone as monotherapy or in combination with other therapeutic agents, depending on the specific cancer type and stage. It opens doors to new possibilities in cancer treatment, offering a more sustainable and effective approach.

Thetis Pharmaceuticals’ approach extends beyond conventional treatments by exploring RvE1’s potential as an adjuvant or neo-adjuvant therapy. This means it can be used alongside surgery or radiation therapy, potentially enhancing their efficacy while minimizing side effects. Additionally, combining RvE1 with immune checkpoint inhibitors represents another frontier in cancer treatment, leveraging the synergistic effects to boost the body’s immune response against cancer cells.

The company will conduct a Phase 1 study in healthy volunteers in 2024 and follow it up with a patient study in mild-to-moderate IBD and solid tumor cancers in 2025. 

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts